drugset / Trial / NCT05141357
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Timeline
- Start
- 2022-02-15
- Primary completion
- 2023-04-19
- Completion
- 2023-04-19
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |